|
Colorectal Carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Colorectal Carcinoma
|
|
0.720 |
GeneticVariation
|
GWASCAT |
We also identified 2 risk variants at loci previously associated with CRC: 10q25.2 (rs10506868) and 20q13.3 (rs6061231).
|
26965516 |
2016 |
|
Colorectal Carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
We also identified 2 risk variants at loci previously associated with CRC: 10q25.2 (rs10506868) and 20q13.3 (rs6061231).
|
26965516 |
2016 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
Colorectal Neoplasms
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
Malignant tumor of colon
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
Malignant neoplasm of large intestine
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
Adenocarcinoma of large intestine
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.
|
26965516 |
2016 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Glioma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |